238 related articles for article (PubMed ID: 19703338)
1. Prognostic and predictive value of p53 in low MGMT expressing glioblastoma treated with surgery, radiation and adjuvant temozolomide chemotherapy.
Li S; Zhang W; Chen B; Jiang T; Wang Z
Neurol Res; 2010 Sep; 32(7):690-4. PubMed ID: 19703338
[TBL] [Abstract][Full Text] [Related]
2. Immunohistochemical analysis of O6-methylguanine-DNA methyltransferase (MGMT) protein expression as prognostic marker in glioblastoma patients treated with radiation therapy with concomitant and adjuvant Temozolomide.
Younis SG; Khedr RA; El-Shorbagy SH
J Egypt Natl Canc Inst; 2016 Mar; 28(1):23-30. PubMed ID: 26682634
[TBL] [Abstract][Full Text] [Related]
3. The impact of sequential vs. combined radiochemotherapy with temozolomide, resection and MGMT promoter hypermethylation on survival of patients with primary glioblastoma--a single centre retrospective study.
Rapp M; Goeppert M; Felsberg J; Steiger HJ; Sabel M
Br J Neurosurg; 2013 Aug; 27(4):430-5. PubMed ID: 23418781
[TBL] [Abstract][Full Text] [Related]
4. MGMT gene promoter methylation as a potent prognostic factor in glioblastoma treated with temozolomide-based chemoradiotherapy: a single-institution study.
Kim YS; Kim SH; Cho J; Kim JW; Chang JH; Kim DS; Lee KS; Suh CO
Int J Radiat Oncol Biol Phys; 2012 Nov; 84(3):661-7. PubMed ID: 22414280
[TBL] [Abstract][Full Text] [Related]
5. The correlation and prognostic significance of MGMT promoter methylation and MGMT protein in glioblastomas.
Cao VT; Jung TY; Jung S; Jin SG; Moon KS; Kim IY; Kang SS; Park CS; Lee KH; Chae HJ
Neurosurgery; 2009 Nov; 65(5):866-75; discussion 875. PubMed ID: 19834398
[TBL] [Abstract][Full Text] [Related]
6. Impact of p53 status to response of temozolomide in low MGMT expression glioblastomas: preliminary results.
Li S; Jiang T; Li G; Wang Z
Neurol Res; 2008 Jul; 30(6):567-70. PubMed ID: 18647495
[TBL] [Abstract][Full Text] [Related]
7. Volumetric and MGMT parameters in glioblastoma patients: survival analysis.
Iliadis G; Kotoula V; Chatzisotiriou A; Televantou D; Eleftheraki AG; Lambaki S; Misailidou D; Selviaridis P; Fountzilas G
BMC Cancer; 2012 Jan; 12():3. PubMed ID: 22214427
[TBL] [Abstract][Full Text] [Related]
8. Permeability Surface Area Product Using Perfusion Computed Tomography Is a Valuable Prognostic Factor in Glioblastomas Treated with Radiotherapy Plus Concomitant and Adjuvant Temozolomide.
Saito T; Sugiyama K; Ikawa F; Yamasaki F; Ishifuro M; Takayasu T; Nosaka R; Nishibuchi I; Muragaki Y; Kawamata T; Kurisu K
World Neurosurg; 2017 Jan; 97():21-26. PubMed ID: 27693246
[TBL] [Abstract][Full Text] [Related]
9. Molecular-Based Recursive Partitioning Analysis Model for Glioblastoma in the Temozolomide Era: A Correlative Analysis Based on NRG Oncology RTOG 0525.
Bell EH; Pugh SL; McElroy JP; Gilbert MR; Mehta M; Klimowicz AC; Magliocco A; Bredel M; Robe P; Grosu AL; Stupp R; Curran W; Becker AP; Salavaggione AL; Barnholtz-Sloan JS; Aldape K; Blumenthal DT; Brown PD; Glass J; Souhami L; Lee RJ; Brachman D; Flickinger J; Won M; Chakravarti A
JAMA Oncol; 2017 Jun; 3(6):784-792. PubMed ID: 28097324
[TBL] [Abstract][Full Text] [Related]
10. Temozolomide in elderly patients with newly diagnosed glioblastoma and poor performance status: an ANOCEF phase II trial.
Gállego Pérez-Larraya J; Ducray F; Chinot O; Catry-Thomas I; Taillandier L; Guillamo JS; Campello C; Monjour A; Cartalat-Carel S; Barrie M; Huchet A; Beauchesne P; Matta M; Mokhtari K; Tanguy ML; Honnorat J; Delattre JY
J Clin Oncol; 2011 Aug; 29(22):3050-5. PubMed ID: 21709196
[TBL] [Abstract][Full Text] [Related]
11. Immunohistochemical profiles of IDH1, MGMT and P53: practical significance for prognostication of patients with diffuse gliomas.
Ogura R; Tsukamoto Y; Natsumeda M; Isogawa M; Aoki H; Kobayashi T; Yoshida S; Okamoto K; Takahashi H; Fujii Y; Kakita A
Neuropathology; 2015 Aug; 35(4):324-35. PubMed ID: 25950388
[TBL] [Abstract][Full Text] [Related]
12. Long-term outcomes of concomitant chemoradiotherapy with temozolomide for newly diagnosed glioblastoma patients: A single-center analysis.
Roh TH; Park HH; Kang SG; Moon JH; Kim EH; Hong CK; Ahn SS; Choi HJ; Cho J; Kim SH; Lee SK; Kim DS; Kim SH; Suh CO; Lee KS; Chang JH
Medicine (Baltimore); 2017 Jul; 96(27):e7422. PubMed ID: 28682902
[TBL] [Abstract][Full Text] [Related]
13. Prospective cohort study of radiotherapy with concomitant and adjuvant temozolomide chemotherapy for glioblastoma patients with no or minimal residual enhancing tumor load after surgery.
Stummer W; Meinel T; Ewelt C; Martus P; Jakobs O; Felsberg J; Reifenberger G
J Neurooncol; 2012 May; 108(1):89-97. PubMed ID: 22307805
[TBL] [Abstract][Full Text] [Related]
14. Survival Outcomes of Elderly Patients With Glioblastoma Multiforme in Their 75th Year or Older Treated With Adjuvant Therapy.
Harris G; Jayamanne D; Wheeler H; Gzell C; Kastelan M; Schembri G; Brazier D; Cook R; Parkinson J; Khasraw M; Louw S; Back M
Int J Radiat Oncol Biol Phys; 2017 Jul; 98(4):802-810. PubMed ID: 28602411
[TBL] [Abstract][Full Text] [Related]
15. Prognostic significance of O6-methylguanine-DNA methyltransferase protein expression in patients with recurrent glioblastoma treated with temozolomide.
Nagane M; Kobayashi K; Ohnishi A; Shimizu S; Shiokawa Y
Jpn J Clin Oncol; 2007 Dec; 37(12):897-906. PubMed ID: 18156172
[TBL] [Abstract][Full Text] [Related]
16. MGMT promoter methylation correlates with survival benefit and sensitivity to temozolomide in pediatric glioblastoma.
Donson AM; Addo-Yobo SO; Handler MH; Gore L; Foreman NK
Pediatr Blood Cancer; 2007 Apr; 48(4):403-7. PubMed ID: 16609952
[TBL] [Abstract][Full Text] [Related]
17. Clinical significance of molecular biomarkers in glioblastoma.
Ang C; Guiot MC; Ramanakumar AV; Roberge D; Kavan P
Can J Neurol Sci; 2010 Sep; 37(5):625-30. PubMed ID: 21059509
[TBL] [Abstract][Full Text] [Related]
18. Predominant influence of MGMT methylation in non-resectable glioblastoma after radiotherapy plus temozolomide.
Thon N; Eigenbrod S; Grasbon-Frodl EM; Lutz J; Kreth S; Popperl G; Belka C; Kretzschmar HA; Tonn JC; Kreth FW
J Neurol Neurosurg Psychiatry; 2011 Apr; 82(4):441-6. PubMed ID: 20861061
[TBL] [Abstract][Full Text] [Related]
19. MGMT in primary and recurrent human glioblastomas after radiation and chemotherapy and comparison with p53 status and clinical outcome.
Wiewrodt D; Nagel G; Dreimüller N; Hundsberger T; Perneczky A; Kaina B
Int J Cancer; 2008 Mar; 122(6):1391-9. PubMed ID: 18000822
[TBL] [Abstract][Full Text] [Related]
20. MEK-ERK signaling dictates DNA-repair gene MGMT expression and temozolomide resistance of stem-like glioblastoma cells via the MDM2-p53 axis.
Sato A; Sunayama J; Matsuda K; Seino S; Suzuki K; Watanabe E; Tachibana K; Tomiyama A; Kayama T; Kitanaka C
Stem Cells; 2011 Dec; 29(12):1942-51. PubMed ID: 21957016
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]